Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00379353 · ClinicalTrials.gov registry record · Phase 2
The Effects of Thalidomide on Symptom Clusters
A Phase 2 study of Advanced Cancers, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT00379353: Completed Phase 2 study of Advanced Cancers, sponsored by M.D. Anderson Cancer Center.
NCT00379353 is a Phase 2 study of Advanced Cancers that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 32 participants, below the 67-participant average among 10 other Advanced Cancers trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00379353, a Phase 2 study of Advanced Cancers, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if thalidomide can improve symptoms such as pain, fatigue,anxiety, poor appetite, depression, and sleep problems in patients with advanced cancer.
Primary Outcome
ESAS assessment of appetite (symptom) where the severity at the time of assessment is rated from 0 to 10 on a numerical scale; with 0 meaning that the symptom is absent and 10 that it is the worst possible severity. Evaluated at baseline \[± 3 days\], 2 weeks\[± 3 days\] and 4 weeks \[± 3 days\]
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Thalidomide
Study Locations (1)
Texas
- UT MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2006-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
What the finished NCT00379353 record still lists
NCT00379353 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 67-participant average among 10 other Advanced Cancers trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Advanced Cancers appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00379353 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00379353 about?
NCT00379353 is a clinical study titled "The Effects of Thalidomide on Symptom Clusters". The goal of this clinical research study is to learn if thalidomide can improve symptoms such as pain, fatigue,anxiety, poor appetite, depression, and sleep problems in patients with advanced cancer.
What is the current status of trial NCT00379353?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2006-09. Estimated completion is 2013-01.
What conditions does trial NCT00379353 study?
This clinical trial studies the following conditions: Advanced Cancers.
What interventions are being tested in trial NCT00379353?
The interventions under investigation include: Placebo (DRUG), Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00379353?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00379353 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00379353's enrollment target sits among peer trials
32 7th of 10 higher than 4 of 10 other Advanced Cancers trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
The Effects of Ginseng on Cancer-Related Fatigue
ACTIVE NOT RECRUITING · Phase 1
-
Study of Vemurafenib, Carboplatin, and Paclitaxel
COMPLETED · Phase 1
-
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia